Search Results - "ПЕРИФЕРИЧЕСКАЯ НЕРВНАЯ СИСТЕМА"

Relation: Обзорный цикл лекций по анатомии человека / О. А. Шерстюк, Н. Л. Свинцицкая, А. В. Пилюгин [и др.]. – Полтава, 2021. – 194 с.; https://repository.pdmu.edu.ua/handle/123456789/14928

Availability: https://repository.pdmu.edu.ua/handle/123456789/14928

View record from BASE

7

Academic Journal

PECULIARITIES OF HUMAN GASTRIC NERVE MORPHOGENESIS

Source: Clinical anatomy and operative surgery; Vol. 3 No. 4 (2004); 42-48
Клиническая анатомия и оперативная хирургия; Том 3 № 4 (2004); 42-48
Клінічна анатомія та оперативна хірургія; Том 3 № 4 (2004); 42-48

Subject Terms: периферическая нервная система, блуждающий нерв, миелоархитектоника, желудок, периферійна нервова система, блукаючий нерв, мієлоархітектоніка, шлунок, peripheral nervous system, vagus, myeloarchitectonics, stomach

File Description: application/pdf

Access URL: http://kaos.bsmu.edu.ua/article/view/263663

View record at OpenAIRE

8

Academic Journal

Fatigue in patients with chronic inflammatory demyelinating polyneuropathy ; Астения у пациентов, страдающих хронической воспалительной демиелинизирующей полиневропатией

Authors: R. A. Gapeshin, E. R. Barantsevich, D. I. Rudenko, T. R. Stuchevskaya, E. A. Gavrilova, M. S. Pushkaryov, A. A. Yakovlev, A. V. Gavrichenko, A. G. Smochilin, Р. А. Гапешин, Е. Р. Баранцевич, Д. И. Руденко, Т. Р. Стучевская, Е. А. Гаврилова, М. С. Пушкарёв, А. А. Яковлев, А. В. Гавриченко, А. Г. Смочилин

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 1 (2021); 51-56 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 1 (2021); 51-56 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-1

Subject Terms: периферическая нервная система, fatigue, electroneuromyography, neuropathy, peripheral nervous system, астения, электронейромиография, невропатия

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1507/1183; https://nnp.ima-press.net/nnp/article/view/1507/1184; Khoo A, Frasca J, Schultz D. Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Biomark Res. 2019;7(1):1-8. doi:10.1186/s40364-0190154-2; Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complicat. Sep-Oct 2016;30(7):1401-7. doi:10.1016/j.jdiacomp.2016.05.007. Epub 2016 May 10.; Broers MC, Bunschoten C, Nieboer D, et al. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-72. doi:10.1159/000494291; Попова ТЕ, Шнайдер НА, Петрова ММ и др. Эпидемиология хронической воспалительной демиелинизирующей полиневропатии за рубежом и в России. Нервно-мышечные болезни. 2015;5(2):10-5. doi:10.17650/2222-8721-2015-5-2-10-15; Турсынов НИ, Григолашвили МА, Илюшина МЮ и др. Современные аспекты диагностики и лечения хронических демиелинизирующих полинейропатий. Нейрохирургия и неврология Казахстана. 2016;3(44):38-45.; Щукин ИА, Лебедева АВ, Чубыкин ВИ и др. Астения у пациентов с хроническими неврологическими заболеваниями. Клиницист. 2013;7(2):64-72. doi:10.17650/18188338-2013-2-64-72; Lawley A, Abbas A, Seri S, Rajabally YA. Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;62(2):226-32. doi:10.1002/mus.26913; Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol. 2010;17(3):356-63. doi:10.1111/j.1468-1331.2009.02930.x; Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49(1):229-39. doi:10.1212/wnl.49.1.229; Kleyweg RP, Meche FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength Guillain-Barre syndrome. Muscle Nerve. 1991 Nov;14(11):1103-9. doi:10.1002/mus.880141111; Alabdali M, Abraham A, Alsulaiman A, et al. Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. J Neurol Sci. 2017 Jan 15;372:223-7. doi:10.1016/j.jns.2016.11.056. Epub 2016 Nov 23.; Merkies ISJ, Kieseier BC. Fatigue, pain, anxiety and depression in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol. 2016;75(3-4):199-206. doi:10.1159/000445347; Gavrilov YuV, Shkilnyuk GG, Valko PO, et al. Validation of the Russian Version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients. Acta Neurol Scand. 2018 Nov;138(5):408-416. doi:10.1111/ane.12993. Epub 2018 Jul 9.; Chaudhuri A, Behan P. Fatigue in neurological disorders. Lancet. 2004 Mar 20;363(9413):978-88. doi:10.1016/S01406736(04)15794-2; Zwarts MJ, Bleijenberg G, van Engelen BGM. Clinical neurophysiology of fatigue. Clin Neurophysiol. 2008 Jan;119(1):2-10. doi:10.1016/j.clinph.2007.09.126. Epub 2007 Nov 26.; Kent-Braun JA, Le Blanc R. Quantitation of Central Activation Failure During Maximal Volintary Contractions in Humans. Muscle Nerve. 1996 Jul;19(7):861-9. doi:10.1002/(SICI)10974598(199607)19:73.0.CO;2-7; Garssen MPJ, Schillings ML, van Doorn PA, et al. Contributions of Central and Peripheral Factors to Residual Fatigue in Guillain-Barre Syndrome. Muscle Nerve. 2007 Jul;36(1):93-9. doi:10.1002/mus.20739; Boukhris S, Magy L, Gallouedec G, et al. Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: A study of 11 cases. J Peripher Nerv Syst. 2005 Sep;10(3):329-37. doi:10.1111/j.1085-9489.2005.10311.x; Westblad ME, Forsberg A, Press R. Disability and health status in patients with chronic inflammatory demyelinating polyneuropathy. Disabil Rehabil. 2009;31(9):720-5. doi:10.1080/09638280802306497; Gable KL, Attarian H, Allen JA. Fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020 Dec;62(6):673-80. doi:10.1002/mus.27038. Epub 2020 Aug 10.; Merkies IS, Schmitz PI, Samijn JP, et al. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 1999;53(8):1648-54. doi:10.1212/WNL.53.8.1648; Li SH, Lloyd AR, Graham BM. Physical and mental fatigue across the menstrual cycle in women with and without generalized anxiety disorder. Horm Behav. 2020 Feb;118:104667. doi:10.1016/j.yhbeh.2019.104667. Epub 2020 Jan 8.; Garssen MP, Bussmann JB, Schmitz PI, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barrе syndrome and CIDP. Neurology. 2004 Dec 28;63(12):2393-5. doi:10.1212/01.wnl.0000148589.87107.9c; Markvardsen LK, Carstens A-KR, Knak KL, et al. Muscle Strenght and Aerobic Capacity in Patients with CIDP One Year after Participation in an Exercise Trial. J Neuromuscular Dis. 2019;6(1):93-7. doi:10.3233/JND-180344

Availability: https://nnp.ima-press.net/nnp/article/view/1507
https://doi.org/10.14412/2074-2711-2021-1-51-56

View record from BASE

9

Academic Journal

Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes ; Диагностика и лечение поражений периферической нервной системы у пациентов с предиабетом

Authors: O. E. Zinovyeva, T. M. Ostroumova, M. V. Koniashova, N. A. Gorbachev, О. Е. Зиновьева, Т. М. Остроумова, М. В. Коняшова, Н. А. Горбачев

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 5 (2021); 116-122 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 5 (2021); 116-122 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-5

Subject Terms: альфа-липоевая кислота, diabetic neuropathy, peripheral nervous system, alpha-lipoic acid, диабетическая невропатия, периферическая нервная система

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1675/1320; Шестакова МВ, Викулова ОК, Железнякова АВ и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019;91(10):4-13. doi:10.26442/00403660.2019.10.000364; Дедов ИИ, Шестакова МВ, Майоров АЮ и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4-102. doi:10.14341/DM12507; Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi:10.1093/eurheartj/ehz486; International Diabetes Federation. IDF Diabetes Atlas, 9 th ed. Brussels, Belgium: 2019. Available from: https://www.diabetesatlas.org; Pfannkuche A, Alhajjar A, Ming A, et al. Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative «diabetes and nerves». Endocr Metab Sci. 2020 Jul;1(1-2):100053. doi:10.1016/j.endmts.2020.100053; Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017 Sep;8(5):646-55. doi:10.1111/jdi.12650; Kirthi V, Perumbalath A, Brown E, et al. Prevalence of peripheral neuropathy in pre-diabetes: a systematic review. BMJ Open Diabetes Res Care. 2021 May;9(1):e002040. doi:10.1136/bmjdrc-2020-002040; American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021 Jan;44(Suppl. 1):S15-S33. doi:10.2337/dc21-S002; Barrell K, Smith AG. Peripheral Neuropathy. Med Clin North Am. 2019 Mar;103(2):383-97. doi:10.1016/j.mcna.2018.10.006; Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008 Mar;31(3):464-9. doi:10.2337/dc07-1796; Kazamel M, Stino AM, Smith AG. Metabolic syndrome and peripheral neuropathy. Muscle Nerve. 2021 Mar;63(3):285-93. doi:10.1002/mus.27086; Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009 Mar;10(2):393-400. doi:10.1111/j.1526-4637.2008.00555.x; Lee CC, Perkins BA, Kayaniyil S, et al. Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015 May;38(5):793-800. doi:10.2337/dc14-2585; Spallone V. Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet. Diabetes Metab J. 2019 Feb;43(1):3-30. doi:10.4093/dmj.2018.0259; Ziegler D, Voss A, Rathmann W, et al. Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia. 2015 May;58(5):1118-28. doi:10.1007/s00125-015-3534-7; Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136-54. doi:10.2337/dc16-2042; Дедов ИИ, Шестакова МВ, Майоров АЮ, редакторы. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: Клинические рекомендации. 9-й выпуск. Сахарный диабет. 2019;22(1S1):1-144. doi:10.14341/DM221S1; American Diabetes Association. Microvascular complications and foot care: Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021 Jan;44(Suppl. 1):S151-S167. doi:10.2337/dc21-S011; Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diab Rep. 2012 Aug;12(4):376-83. doi:10.1007/s11892-012-0278-3; Zeng J, Xu Y, Shi Y, Jiang C. Inflammation role in sensory neuropathy in Chinese patients with diabetes/prediabetes. Clin Neurol Neurosurg. 2018 Mar;166:136-40. doi:10.1016/j.clineuro.2018.01.031; Van der Velde JHPM, Koster A, Strotmeyer ES, et al. Cardiometabolic risk factors as determinants of peripheral nerve function: the Maastricht Study. Diabetologia. 2020 Aug;63(8):1648-58. doi:10.1007/s00125-020-05194-5; Kopf S, Groener JB, Kender Z, et al. Deep phenotyping neuropathy: An underestimated complication in patients with pre-diabetes and type 2 diabetes associated with albuminuria. Diabetes Res Clin Pract. 2018 Dec;146:191-201. doi:10.1016/j.diabres.2018.10.020; Thaisetthawatkul P, Fernandes Filho JA, Herrmann DN. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve. 2013 Dec;48(6):883-8. doi:10.1002/mus.23891; McArthur JC. Painful small fiber neuropathies. Continuum (Minneap Minn). 2012 Feb;18(1):106-25. doi:10.1212/01.CON.0000411570.79827.25; Divisova S, Vlckova E, Hnojcikova M, et al. Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres. J Peripher Nerv Syst. 2012 Sep;17(3):341-50. doi:10.1111/j.1529-8027.2012.00420.x; Asghar O, Petropoulos IN, Alam U, et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care. 2014 Sep;37(9):2643-6. doi:10.2337/dc14-0279; DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011 Mar;37(3):588-98. doi:10.1016/j.jcrs.2010.12.037; Jende JME, Kender Z, Mooshage C, et al. Diffusion Tensor Imaging of the Sciatic Nerve as a Surrogate Marker for Nerve Functionality of the Upper and Lower Limb in Patients With Diabetes and Prediabetes. Front Neurosci. 2021 Mar;15:642589. doi:10.3389/fnins.2021.642589; Suo M, Wang P, Zhang M. Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice. J Neurophysiol. 2016 Aug;116(2):448-55. doi:10.1152/jn.00229.2016; Hinder LM, O'Brien PD, Hayes JM, et al. Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. Dis Model Mech. 2017 Jun;10(6):717-25. doi:10.1242/dmm.028530; Roncero-Ramos I, Alcala-Diaz JF, Rangel-Zuniga OA, et al. Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation: The CORDIOPREV study. Clin Nutr. 2020 Feb;39(2):492-500. doi:10.1016/j.clnu.2019.02.027; Hemmingsen B, Gimenez-Perez G, Mauricio D, et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD003054. doi:10.1002/14651858.CD003054.pub4; Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019 Jun;7(6):452-61. doi:10.1016/S2213-8587(19)30093-2; Nathan DM, Barrett-Connor E, Crandall JP, et al. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-75. doi:10.1016/S2213-8587(15)00291-0; Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006 Jun;29(6):1294-9. doi:10.2337/dc06-0224; Groover AL, Ryals JM, Guilford BL, et al. Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain. 2013 Dec;154(12):2658-67. doi:10.1016/j.pain.2013.07.052; Carnethon MR, Prineas RJ, Temprosa M, et al. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006 Apr;29(4):914-9. doi:10.2337/diacare.29.04.06.dc05-1729; Madsen KS, Chi Y, Metzendorf MI, et al. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019 Dec;12(12):CD008558. doi:10.1002/14651858.CD008558.pub2; Moelands SV, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018 Dec;12(12):CD005061. doi:10.1002/14651858.CD005061.pub3; Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 May;5(5):CD012204. doi:10.1002/14651858.CD012204.pub2; Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind. World J Diabetes. 2021 Jul;12(7):916-31. doi:10.4239/wjd.v12.i7.916; Inzucchi SE, Docherty KF, Kњber L, et al. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2021 Feb;44(2):586-94. doi:10.2337/dc20-1675; Gabriel R, Boukichou Abdelkader N, Acosta T, et al. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. PLoS One. 2020 Apr;15(4):e0231196. doi:10.1371/journal.pone.0231196; Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019 Jun;5(1):41. doi:10.1038/s41572-019-0092-1; Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014 Feb;80:21-35. doi:10.1016/j.phrs.2013.12.005; Rahimlou M, Asadi M, Banaei Jahromi N, Mansoori A. Alpha-lipoic acid (ALA) supplementation effect on glycemic and inflammatory biomarkers: A Systematic Review and meta-analysis. Clin Nutr ESPEN. 2019 Aug;32:16-28. doi:10.1016/j.clnesp.2019.03.015; Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012 Oct;167(4):465-71. doi:10.1530/EJE-12-0555; Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 year in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi:10.2337/dc11-0503; Gosselin LE, Chrapowitzky L, Rideout TC. Metabolic effects of α-lipoic acid supplementation in pre-diabetics: a randomized, placebo-controlled pilot study. Food Funct. 2019 Sep;10(9):5732-8. doi:10.1039/c9fo00390h; Haghighatdoost F, Hariri M. Does alpha-lipoic acid affect lipid profile? A meta-analysis and systematic review on randomized controlled trials. Eur J Pharmacol. 2019 Mar;847:1-10. doi:10.1016/j.ejphar.2019.01.001

Availability: https://nnp.ima-press.net/nnp/article/view/1675
https://doi.org/10.14412/2074-2711-2021-5-116-122

View record from BASE

10

Academic Journal

Features of nervous system damage in antiphospholipid syndrome ; Особенности поражения нервной системы при антифосфолипидном синдроме

Source: Obstetrics, Gynecology and Reproduction; Vol 15, No 4 (2021); 404-414 ; Акушерство, Гинекология и Репродукция; Vol 15, No 4 (2021); 404-414 ; 2500-3194 ; 2313-7347

File Description: application/pdf

Relation: https://www.gynecology.su/jour/article/view/1069/933; Гри Ж.-К., Макацария А.Д., Бицадзе В.О. и др. Антифосфолипидный синдром и беременность. Акушерство и гинекология. 2018;(10):5-11. https://doi.org/10.18565/aig.2018.10.5-11.; Vila P., Hernandez M.C., Lopez-Fernandez M.F., Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72(2):209-13.; Макацария А.Д., Бицадзе В.О., Хизроева Д.Х. и др. Патогенетическое значение антифосфолипидных антител. Практическая медицина. 2012;(5):9-21.; Fleetwood T., Cantello R., Comi C. Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy. Front Neurol. 2018;9:1001.; Gris J.-Ch., Nobile B., Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thrombs Res. 2015;135(Suppl 1):S56-9. https://doi.org/10.1016/S0049-3848(15)50445-3.; Katzav A., Pick C.G., Korczyn A.D. et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001;10(7):496-9. https://doi.org/10.1191/096120301678416060.; Chapman J., Cohen-Armon M., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 1999;8(2):127-33. https://doi.org/10.1191/096120399678847524.; Блинов Д.В. Современные представления о роли нарушения резистентности гематоэнцефалического барьера в патогенезе заболеваний ЦНС. Часть 1: строение и формирование гематоэнцефалического барьера. Эпилепсия и пароксизмальные состояния. 2013;5(3):65-75.; Блинов Д.В. Современные представления о роли нарушения резистентности гематоэнцефалического барьера в патогенезе заболеваний ЦНС. Часть 2: функции и механизмы повреждения гематоэнцефалического барьера. Эпилепсия и пароксизмальные состояния. 2014;6(1):70-84. https://doi.org/; Блинов Д.В. Пациенты с неврологическими расстройствами: обоснование необходимости фармакоэкономической оценки оптимизации затрат на ведение с использованием нейроспецифических белков в качестве маркеров повышения проницаемости гематоэнцефалического барьера. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2014;7(1):40-5.; Маджидова Ё.Н., Рахимбаева Г.С., Азизова Р.Б. Нейроиммунопатогенетические механизмы эпилепсии. Эпилепсия и пароксизмальные состояния. 2014;6(1):15-8.; Huseynova S., Mukhtarova S., Alasgarova S. AO-40. Acute brain injury of very low birthweight infants born to mothers with autoimmune disorders in pregnancy. Early Human Development. 2010;86:S16. https://doi.org/10.1016/j.earlhumdev.2010.09.048.; Frauenknecht K., Katzav A., Grimm C. et al. Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors. Immunobiology. 2013;218(4):517-26. https://doi.org/10.1016/j.imbio.2012.06.011.; Yaremchuk O.Z., Posokhova K.A., Tokarskyi O.S. The influence of L-arginine on the level of synthesis of nitric oxide and the content of glial fibrillary acidic protein in brain during experimental antiphospholipid syndrome. Scientific Issue Ternopil Volodymyr Hnatiuk National Pedagogical University. Series: Biology. 2019;77(3):39-45. https://doi.org/10.25128/2078-2357.19.3.5.; Yaremchuk O., Soroka Yu., Kulitska M. et al. Neuroprotective effect of aminoguanidine in experimental obstetric antiphospholipid syndrome. Georgian Med News. 2020;(301):159-65.; Rajput P.S., Lyden P.D., Chen B. et al. Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models. Neuroscience. 2014;281;229-40. https://doi.org/10.1016/j.neuroscience.2014.09.038.; Cervera R., Boffa M.C., Khamashta M.A., Hughes G.R. The EuroPhospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009;18(10):889-93. https://doi.org/10.1177/0961203309106832.; Kenet G., Sadetzki S., Murad H. et al. Leiden and antiphopholipid antibodies are significant risk factors for ischemic stroke in children. Stroke. 2000;31(6):1283-8. https://doi.org/10.1161/01.str.31.6.1283.; Sciascia S., Sanna G., Khamashta M.A. et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheumat Dis. 2015;74(11):2028-33. https://doi.org/10.1136/annrheumdis-2014-205663.; Калашникова Л.А. Неврология антифосфолипидного синдрома. Медицина. М.: Медицина, 2003. 256 с.; Khamashta M.A., Cervera R., Asherson R.A. et al. Association of antibodies against phospholipids with valvular heart disease in patients with systemic lupus erythematosus. Lancet. 1990;335(8705):1541-4. https://doi.org/10.1016/0140-6736(90)91373-i.; Provenzale J.M., Barboriak D.P., Allen N.B., Ortel T.L. Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am J Roentgenol. 1996;167(6):1573-8. https://doi.org/10.2214/ajr.167.6.8956600.; Тухфатуллина С.И., Гайнетдинова Д.Д. Ишемические и неишемические проявления при антифосфолипидном синдроме. Казанский медицинский журнал. 2015;96(1):61-9. https://doi.org/10.17750/KMJ2015-061.; Беденко А.С. Вестибулярная мигрень как причина головокружения: актуальные проблемы патогенеза, диагностики и терапии. Эпилепсия и пароксизмальные состояния. 2020;12(3):177-81. https://doi.org/10.17749/2077-8333/epi.par.con.2020.032.; Калашникова Л.А. Неишемические неврологические проявления у больных первичным антифосфолипидным синдромом. Журнал неврологии и психиатрии имени С.С. Корсакова. 2005;105(2):18-23.; Hughes G.R.V. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J. 2003;79(928):81-3. https://doi.org/10.1136/pmj.79.928.81.; Табеева Г.Р. Мигрень и цереброваскулярная патология. Справочник поликлинического врача. 2014;(3):45.; Карлов В.А. Российская Противоэпилептическая Лига сегодня: вызов времени. Эпилепсия и пароксизмальные состояния. 2020;12(1):5.; Что удалось и чего не удалось достичь в 2020 году. Эпилепсия и пароксизмальные состояния. 2021;13(1):5.; Карлов В.А. Российская Противоэпилептическая Лига: ответ на вызов времени. Эпилепсия и пароксизмальные состояния. 2021;13(1S):88-90. https://doi.org/10.17749/2077-8333/epi.par.con.2021.085.; Михаловска-Карлова Е.П. Биоэтическое сопровождение лечения пациентов с эпилепсией: гендерные и возрастные аспекты. Эпилепсия и пароксизмальные состояния. 2020;12(2):117-21. https://doi.org/10.17749/2077-8333/epi.par.con.2020.039.; Noureldine M.H., Harifi G., Berjawi A. et al. Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? Lupus. 2016;25(13):1397-411. https://doi.org/10.1177/0961203316651747.; de Carvalho J.F., Pasoto S.G., Appenzeller S. Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke. Clin Dev Immunol. 2012;2012:981519. https://doi.org/10.1155/2012/98151.; Carecchio M, Cantello R, Comi C. Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage. J Immunol Res. 2014;2014:239398. https://doi.org/10.1155/2014/239398.; Rodrigues C.E., de Carvalho J.F. Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature. Semin Arthritis Rheum. 2011;40(4):349-57. https://doi.org/10.1016/j.semarthrit.2010.05.004.; Brey R.L., Muscal E., Chapman J. Antiphospholipid antibodies and the brain: a consensus report. Lupus. 2011;20(20):153-7. https://doi.org/10.1177/0961203310396748.; Cervera R., Piette J.C., Font J. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-27. https://doi.org/10.1002/art.10187.; Sanna G., Bertolaccini M.L., Cuadrado M.J. et al. Central nervous system involvement in the antiphopholipid (Hughes) syndrome. Rheumatology (Oxford). 2003;42(2):200-13. https://doi.org/10.1093/rheumatology/ keg080.; Santos M.S., de Carvalho J.F., Brotto M. et al. Peripheral neuropathy in patients with primary antiphospholipid (Hughes') syndrome. Lupus. 2010;19(5):583-90. https://doi.org/10.1177/0961203309354541.; Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-509. https://doi.org/10.1016/S0140-6736(10)60709-X.; Arachchillage D.J., Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep. 2013;15(6):331. https://doi.org/10.1007/s11926-013-0331-5.; Сатыбалдыева М.А., Решетняк Т.М. Новые оральные антикоагулянты в терапии антифосфолипидного синдрома. Научно-практическая ревматология. 2016;54(2):219-26. https://doi.org/10.14412/1995-4484-2016-219-226.; Тамм М.В. Коронавирусная инфекция в Москве: прогнозы и сценарии. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(1):43-51. https://doi.org/10.17749/2070-4909.2020.13.1.43-51.; Федорова Е.А., Афанасьев Д.О., Соколов А.В., Лазарев М.П. Влияние информации о заболеваниях (лихорадка Эбола и COVID-19) на фармацевтический сектор России и США. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021;14(2):213-24. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.054.; Ди Ренцо Д.К., Макацария А.Д., Цибизова В.И. и др. О принципах работы перинатального стационара в условиях пандемии коронавируса. Вестник РАМН. 2020;75(1):83-92. https://doi.org/10.15690/vramn1324.; Бицадзе В.О., Суконцева Т.А., Акиньшина С.В. и др. Септический шок. Акушерство, Гинекология и Репродукция. 2020;14(3):314-26. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.169.; Юпатов Е.Ю., Мальцева Л.И., Юсупова Н.З. и др. К вопросу о вакцинации беременных женщин в контексте пандемии COVID-19. Акушерство, Гинекология и Репродукция. 2020;14(5):656-66. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.170.; Хизроева Д.Х., Макацария А.Д., Бицадзе В.О. и др. Лабораторный мониторинг COVID-19 и значение определения маркеров коагулопатии. Акушерство, Гинекология и Репродукция. 2020;14(2):132-47. https://doi.org/10.17749/2313-7347.141.; Григорьева К.Н., Бицадзе В.О., Хизроева Д.Х. и др. Синдром активации макрофагов при COVID-19. Акушерство, Гинекология и Репродукция. 2021;15(3):313-20. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.217.; Mehra M., Desai S.S., Kuy S.R. et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382(25):e102. https://doi.org/10.1056/NEJMoa2007621.; Wichmann D., Sperhake J-P., Lutgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268-77. https://doi.org/10.7326/M20-2003.; Solomon I.H., Normandin E., Bhattacharyya S. et al. Neuropathological features of Covid-19. N Engl J Med. 2020;383(10):989-92. https://doi.org/10.1056/NEJMc2019373.; Zhang Y., Xiao M., Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38. https://doi.org/10.1056/NEJMc2007575.; Tung M.L., Tan B., Cherian R., Chandra B. Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. Rheumatol Adv Pract. 2021;5(1):rkaa081. https://doi.org/10.1093/rap/rkaa081.; Delgado-Roche L., Mesta F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Arch Med Res. 2020;51(5):384-7. https://doi.org/10.1016/j.arcmed.2020.04.019.; Lopez-Pedrera C., Barbarroja N., Jimenez-Gomez Y. et al. Oxidative stress in the pathogenesis of atherothrombosis associated with antiphospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. Rheumatology (Oxford). 2016;55(12):2096-108. https://doi.org/10.1093/rheumatology/kew054.; Escher R., Breakey N., Lammle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62. https://doi.org/10.1016/j.thromres.2020.04.014.; Zachariah U., Nair S.C., Goel A. et al. Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid. Thromb Res. 2020;192:2. https://doi.org/10.1016/j.thromres.2020.05.001.; https://www.gynecology.su/jour/article/view/1069

Availability: https://www.gynecology.su/jour/article/view/1069
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.242

View record from BASE

11

Academic Journal

The use of nucleotides in diseases of the peripheral nervous system

Authors: Fister, N.I., Oros, M.M.

Source: INTERNATIONAL NEUROLOGICAL JOURNAL; Vol. 16 No. 8 (2020); 33-36
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; Том 16 № 8 (2020); 33-36
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; Том 16 № 8 (2020); 33-36

Subject Terms: ціанокобаламін, фолиевая кислота, peripheral neuropathic pain, фолієва кислота, цианокобаламин, нуклеотиди, nucleotides, folic acid, peripheral nervous system, периферична нервова система, периферичний нейропатичний біль, уридинмонофосфат, cyanocobalamin, периферическая нервная система, периферическая нейропатическая боль, uridine monophosphate, нуклеотиды

File Description: application/pdf

Access URL: http://inj.zaslavsky.com.ua/article/view/221958

View record at OpenAIRE

12

Academic Journal

Efficiency of anti-B-cell therapy in patients with neuropsychiatric manifestations of systemic lupus erythematosus: a report of clinical cases ; Эффективность анти-В-клеточной терапии у больных с нейропсихическими проявлениями системной красной волчанки (описание клинических случаев)

Contributors: Настоящее исследование выполнено в рамках фунамен-тальной научной темы N AAA-A19-119021190145-2 по фрагменту «РЕНЕССАНС»

Source: Rheumatology Science and Practice; Vol 58, No 1 (2020); 106-111 ; Научно-практическая ревматология; Vol 58, No 1 (2020); 106-111 ; 1995-4492 ; 1995-4484

Subject Terms: анти-В-клеточная терапия, ритуксимаб, neuropsychiatric manifestations, central nervous system, peripheral nervous system, anti-B-cell therapy, rituximab, нейропсихические проявления, центральная нервная система, периферическая нервная система

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2851/1937; Насонов ЕЛ. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. C. 42981; The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599-608. doi:10.1002/1529-0131(199904)42:43.0.CO;2-F; Piga M, Mathieu A. Managing CNS involvement in systemic lupus erythematosus. Int JClin Rheumatol. 2011;6:547-67. doi:10.2217/ijr.11.44; Bortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54(5):891-8. doi:10.1093/rheumatology/keu384; Piga M, Casula L, Perra D, et al. Population-based analysis of hospital-izations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. Lupus. 2016;25:28-37. doi:10.1177/0961203315596597; Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neu-ropsychiat-ric events in systemic lupus erythematosus upon enrollment into an inter-national inception cohort study. Arthritis Rheum. 2008;59(5):721-9. doi:10.1002/art.23566; Zirkzee EJ, Huizinga TW, Bollen EL, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23:31-8. doi:10.1177/0961203313512540; Piga M, Chessa E, Peltz MT, et al. Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev. 2017;16(3):244-52. doi:10.1016/j.autrev.2017.01.011; Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi:10.1002/art.22305; Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommen-da-tions for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-82. doi:10.1136/ard.2010.130476; Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroidsparing regimen. Rheumatology (Oxford). 2012;51(3):476-81. doi:10.1093/rheumatology/ker337; Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treat-ment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717-23. doi:10.1093/ndt/gfp336; Petri M, Orbai A, Alarson G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi:10.1002/art.34473; Shessa E, Piga M, et al. Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab an alternative to standard of care. Open Access Rheumatology: Research and Reviews, 11 September, 2017. P. 167-8. doi:10.2147/OARRR.S143768; Steri M, Orru V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376(17):1615-26. doi:10.1056/NEJMoa1610528; Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382(9894):819-31. doi:10.1016/S0140-6736(13)60954-X; Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev. 2016;15(7):656-63. doi:10.1016/j.autrev.2016.02.019; Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297(5587):1689-92. doi:10.1126/science.1073176; Lovgren T, Eloranta ML, Bave U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861-72. doi:10.1002/art.20254; Martin F, Chan AC. B-cell immunobiology in disease: evolving concepts from the clinic. Ann Rev Immunol. 2006;24:467-96. doi:10.1146/annurev.immunol.24.021605.090517; Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immu-nostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol. 1999;163(11):6306-13.; Piga M, Gabba A, Cauli A, et al. Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultraso-nographic monitoring of response. A longitudinal pilot study. Lupus. 2013;22 (6):624-8. doi:10.1177/0961203313482741; Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364-72. doi:10.1016/j.semarthrit.2011.06.004; Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66 (4):470-5. doi:10.1136/ard.2006.057885; Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-47. doi:10.1038/nrrheum.2014.15; Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41-72. doi:10.1016/j.jaut.2016.06.013; Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484. doi:10.3389/fimmu.2013.00484; Fanouriakis A, Pamfil C, Rednic S, et al. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clin Exp Rheumatol. 2016;34(5):910-7. Epub 2016 Jul 26.; Ho RC, Thiaghu C, Ong H. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016;15:124-38. doi:10.1016/j.autrev.2015.10.003; Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015;13:43. doi:10.1186/s12916-015-0269-8. PMid:25858312; Gladman DD, Urowitz B, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(9):1955-9.; Piga M, Peltz MT, Montaldo C, et al. Twenty-year brain magnetic resonance imaging follow-up study in systemic lupus erythematosus: factors associated with accrual of damage and central nervous system involvement. Autoimmun Rev. 2015;14(6):510-6. doi:10.1016/j.autrev.2015.01.010; Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidi-ties associated with first central nervous system neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicenter retrospective cross sectional study on 959 Italian patients. Rheumatology (Oxford). 2012;51:157-68. doi:10.1093/rheumatology/ker310

Availability: https://rsp.mediar-press.net/rsp/article/view/2851
https://doi.org/10.14412/1995-4484-2020-106-111

View record from BASE

13

Academic Journal

The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with diabetes mellitus ; Особенности хронической воспалительной демиелинизирующей полиневропатии у пациентов с сахарным диабетом

Authors: R. A. Gapeshin, E. R. Barantsevich, D. I. Rudenko, T. R. Stuchevskaya, A. A. Yakovlev, Р. А. Гапешин, Е. Р. Баранцевич, Д. И. Руденко, Т. Р. Стучевская, А. А. Яковлев

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 3 (2020); 24-29 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 3 (2020); 24-29 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-3

Subject Terms: периферическая нервная система, diabetes mellitus, electroneuromyography, neuropathy, peripheral nervous system, сахарный диабет, электронейромиография, невропатия

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1358/1049; Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016 Sep-Oct;30(7):1401-7. doi:10.1016/j.jdiacomp.2016.05.007. Epub 2016 May 10.; Khoo A, Frasca J, Schultz D. Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Biomark Res. 2019 Feb 12;7:3. doi:10.1186/s40364-019-0154-2. eCollection 2019.; Broers MC, Bunschoten C, Nieboer D, et al. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-172. doi:10.1159/000494291. Epub 2019 Jan 22.; Турсынов НИ, Григолашвили МА, Илюшина МЮ и др. Современные аспекты диагностики и лечения хронических демиелинизирующих полинейропатий. Нейрохирургия и неврология Казахстана.2016;(3):38-45.; Rajabally YA, Stettner M, Kieseier BC, et al. Peripheral neuropathies, CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. Nat Rev Neurol. 2017 Oct;13(10):599-611. doi:10.1038/nrneurol.2017.123. Epub 2017 Sep 15.; Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol. 2010 Mar;17(3):356-63. doi:10.1111/j.1468-1331.2009.02930.x.; Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997 Jul;49(1):229-39.; Alabdali M, Abraham A, Alsulaiman A, et al. Clinical characteristics , and impairment and disability scale scores for different CIDP Disease Activity Status classes. J Neurol Sci. 2017 Jan 15;372:223-227. doi:10.1016/j.jns.2016.11.056. Epub 2016 Nov 23.; Kleyweg RP, Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength guillain-barre syndrome. Muscle Nerve. 1991 Nov;14(11):1103-9.; Prodinger B, O'Connor RJ, Stucki G, Tennant A. Establishing score equivalence of the functional independence measure motor scale and the barthel index, utilizing the International classification of functioning, disability and health and rasch measurement theory. J Rehabil Med. 2017 May 16;49(5): 416-22. doi:10.2340/16501977-2225.; Laughlin RS, Dyck PJ, Melton LJ, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009 Jul 7;73(1):39-45. doi:10.1212/WNL.0b013e3181aaea47.; Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007 Dec; 78(12):1349-53. Epub 2007 May 10.; Abraham A, Albulaihe H, Alabdali M, et al. Elevated vibration perception thresholds in CIDP patients indicate more severe neuropathy and lower treatment response rates. PLoS One. 2015 Nov 6;10(11):e0139689. doi:10.1371/journal.pone.0139689. eCollection 2015.; Sharma KR, Cross J, Farronay O, et al. Demyelinating Neuropathy in Diabetes Mellitus. Arch Neurol. 2002. 59: 758-65. https://doi.org/10.1001/archneur.59.5.758.; Dunnigan SK, Ebadi H, Breiner A et al. The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes - An Observational Study. PLoS One. 2014 Feb 19;9(2):e89344. doi:10.1371/journal.pone.0089344. eCollection 2014.; Finsterer J, Aliyev R. Chronic inflammatory demyelinating polyneuropathy variant with creatine-kinase elevation and vanishing effect of immunoglobulins. Am J Case Rep. 2017 Jul 27;18:834-838.; Nevoret M, Vinik AI. CIDP variants in diabetes: measuring treatment response with a small nerve fi ber test. J Diabetes Complications. 2015 Mar;29(2):313-7. doi:10.1016/j.jdiacomp.2014.10.012. Epub 2014 Nov 6.; Dunnigan SK, Ebadi H, Breiner A, et al. Comparison of diabetes patients with «demyeli-nating» diabetic sensorimotor polyneuropathy to those diagnosed with CIDP. Brain Behav. 2013 Nov;3(6):656-63. doi:10.1002/brb3.177. Epub 2013 Sep 22.; Lotan I, Hellman MA, Steiner I. Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus. Acta Neurol Scand. 2015 Oct;132(4):278-83. doi:10.1111/ane.12394. Epub 2015 Mar 25.

Availability: https://nnp.ima-press.net/nnp/article/view/1358
https://doi.org/10.14412/2074-2711-2020-3-24-29

View record from BASE

14

Academic Journal

Перспективы использования кондуитов на основе биокомпозиционных материалов для регенерации нервных проводников

Authors: Парчайкина, М. В., Заварыкина, А. В., Попков, Е. В., Петров, А. А., Ревина, Э. С., Аржанов, Н. Е., Готина, Д. С., Молчанов, И. Д., Ревин, В. В.

Subject Terms: периферическая нервная система, нервные волокна, факторы роста, физиологически активные вещества, биоразлагаемые биоматериалы, технология TERM, регенерация нервных проводников, биокомпозиционные материалы

File Description: application/pdf

Relation: https://elib.belstu.by/handle/123456789/65408; 57:66:62:616.132.2

Availability: https://elib.belstu.by/handle/123456789/65408

View record from BASE

15

Book

Анатомия : Неврология. Анализаторы. Система покровов тела

Subject Terms: неврология, органы чувств, система покровов тела, головной мозг, кожа, анатомия человека, анализаторы, вегетативная нервная система, слуховой анализатор, высшая школа, зрительный анализатор, нервная система, спинной мозг, биология человека, обонятельный анализатор, вестибулярный анализатор, двигательный анализатор, вкусовой анализатор, периферическая нервная система

File Description: application/pdf

Access URL: https://lib.vsu.by/jspui/handle/123456789/19132

16

Academic Journal

Clinical and laboratory manifestations of systemic lupus erythematosus in patients with neuropsychiatric disorders (eurasian renaissance register) ; Клинико-лабораторные особенности системной красной волчанки у пациентов с нейропсихическими нарушениями (Евразийский регистр РЕНЕССАНС)

Source: Rheumatology Science and Practice; Vol 57, No 5 (2019); 532-538 ; Научно-практическая ревматология; Vol 57, No 5 (2019); 532-538 ; 1995-4492 ; 1995-4484

Subject Terms: киргизская когорта, neuropsychiatric manifestations, central nervous system, peripheral nervous system, Kyrgyz cohort, нейропсихические проявления, центральная нервная система, периферическая нервная система

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2787/1891; Насонов ЕЛ. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. С. 429-81.; Vivaldo JF, de Amorim JC, Julio PR, et al. Definition of NPSLE: Does the ACR Nomenclature Still Hold? Front Med (Lausanne). 2018 May;31(5):138. doi:10.3389/fmed.2018.00138. eCollection 2018.; Иванова ММ, Близнюк ОИ, Тодау ФИ, Туманова АА. Поражение центральной нервной системы при системной красной волчанке. Клиническая медицина. 1989;(2):93-7.; Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi:10.1002/art.22305; Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Medicine. 2015;13:48. doi:10.1186/s12916-015-0269-9; The American of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608. doi:10.1002/1529-0131(199904)42:43.0.CO;2-F; Иванова ММ, Близнюк ОИ, Щекутьев ГА, Пушкова ОВ. Диагностика поражения центральной нервной системы у больных системной красной волчанкой. Клиническая ревматология. 1991;(4):6-8.; Zirkzee EJ, Steup-Beekman GM, van der Mast RC, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012;39(11):2118-26. doi:10.3899/jrheum.120545; Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928; Petri M, Orbai A, Alarson G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi:10.1002/art.34473; Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.; Тареева ИЕ, Янушкевич ТН. Волчаночный нефрит у мужчин и женщин. Ревматология. 1985;(2):14-6.; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3 Suppl:1-150.; Zhang X. A study of effects of estrogen receptor and contrasupressor T cell subtype in pathogenesis of SLE. Rev Esp Rheum. 1993;20:420.; Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016;76:459-83. doi:10.1007/s40265-015-0534-3; Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Systemic Lupus International Collaborating Clinics. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi:10.1002/art.22305; Everett CM, Graves TD, Lad S, et al. Aggressive CNS lupus vasculitis in the absence of systemic disease activity. Rheumatology (Oxford). 2008;47:107-9. doi:10.1093/rheumatology/kem264; Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47:337-69. doi:10.1097/00005792-196807000-00002; Kleinig TJ, Koszyca B. Fulminant leucocytoclastic brainstem vasculitis in a patient with otherwise indolent systemic lupus erythematosus. Lupus. 2009;18:486-90. doi:10.1177/0961203308101548; Rizos T, Siegelin M, Hä hnel S, et al. Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2009;18:361-3. doi:10.1177/0961203308097448; Rowshani AT, Remans P, Rozemuller A, Tak PP. Cerebral vasculitis as a primary manifestation of systemic lupus erythematosus. Ann Rheum Dis. 2005;64:784-6. doi:10.1136/ard.2004.026542; Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: Prospective evaluation in a large cohort of Italian patients. Rheumatology. 2002;41:1357-66. doi:10.1093/rheumatology/41.12.1357; Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol. 2002;16(2):229-44. doi:10.1053/berh.2001.0223; Purandare KN, Wagle AC, Parker SR. Psychiatric morbidity in patients with systemic lupus erythematosus. Q J Med. 1999;92:283-6. doi:10.1093/qjmed/92.5.283; Kakati S, Barman B, Ahmed SU, Hussain M. Neurological manifestations in systemic lupus erythematosus: A Single Centre Study from North East India. J Clin Diagn Res Int Med Sect 2017;11(01):OC05-OC09. doi:10.7860/JCDR/2017/23773.9280; Khajezadeh MA, Zamani G, Moazzami B, et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus. Neurol Res Int. 2018 May 29;2548142. doi:10.1155/2018/2548142; Szmyrka M, Pokryszko-Dragan A, Slotwinski K, et al. Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus. Adv Clin Exp Med. 2018 Jul 2. doi:10.17219/acem/76711; Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus. Neurology. 2002;58:1214-20. doi:10.1212/WNL.58.8.1214; Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage systemic lupus erythematosus: data from the Maryland lupus cohort. J Rheumatol. 2004;43:1555-60. doi:10.1093/rheumatology/keh384; Mok CC, Mak A, Chu WP, et al. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore). 2005;84:218-24. doi:10.1097/01.md.0000170022.44998.d1; Whitelaw DA, Spangenberg JJ, Rickman R, et al. Association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus. 1999;8:444-8. doi:10.1177/096120339900800606; Lukjanowcz M, Brzosko M. Myelitis in the course of systemic lupus erythematosus. Polskie Arch Med Wew. 2009;119(1-2):67-72. doi:10.20452/pamw.608; Krishnan C, Kaplin AI, Deshpande DM, et al. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004;9:1483-99. doi:10.2741/1351; Toledano P, Orueta R, Rodriguez-Pinto I, et al. Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and out-come of a large cohort from a single centre. Autoimmun Rev. 2017 Jul;16(7):750-5. doi:10.1016/j.autrev.2017.05.011; Saigal R, Bhargav R, Goyal L, et al. Peripheral neuropathy in systemic lupus erythematosus: Clinical and electrophysiological properties and their association with disease activity parameters. J Assoc Phys India. 2015 Dec;63(12):15-9.; Huynh C, Ho SL, Fong KY, et al. Peripheral neuropathy in systemic lupus erythematosus. J Clin Neurophysiol. 1999;16(2):164-8. doi:10.1097/00004691-199903000-00010; Лайсэк РП, Левинсон АИ. Невропатии при заболеваниях соединительной ткани. Заболевания периферической нервной системы: Пер. с англ. Москва: Медицина; 1987. 280 с.; Mondelli M, Romano C, Porta P, Rossi A. Electrophysiological evidence of «nerve entrapment syndromes» and subclinical peripheral neuropathy in progressive systemic sclerosis. J Neurol. 1995;242:185-94. doi:10.1007/BF00919590

Availability: https://rsp.mediar-press.net/rsp/article/view/2787
https://doi.org/10.14412/1995-4484-2019-532-538

View record from BASE

17

Academic Journal

Neuropsychic manifestations in the Kyrgyz cohort of patients with systemic lupus erythematosus ; Нейропсихические проявления в киргизской когорте больных системной красной волчанкой

Source: Rheumatology Science and Practice; Vol 57, No 1 (2019); 17-27 ; Научно-практическая ревматология; Vol 57, No 1 (2019); 17-27 ; 1995-4492 ; 1995-4484

Subject Terms: киргизская когорта, neuropsychic manifestations, central nervous system, peripheral nervous system, Kyrgyz cohort, нейропсихические проявления, центральная нервная система, периферическая нервная система

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2669/1796; Насонов ЕЛ. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. C. 429-81 [Nasonov EL. Klinicheskie rekomendatsii po revmatologii [Clinical guidelines for rheumatology]. 2nd ed. Moscow: GEOTAR-Media; 2010. P. 429-81 (In Russ.)].; Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014;10(10):579-96. doi:10.1038/nrneurol.2014.148 PMid:25201240; Zhang X. A study of effects of estrogen receptor and contrasupressor T cell subtype in pathogenesis of SLE. Rev Esp Rheum. 1993;20:420.; Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. 2016;76:459-83. doi:10.1007/s40265-015-0534-3 PMid: 26809245; Petri M, Orbai A, Alarson G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi:10.1002/art.34473; The American of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;4:599-608. doi:10.1002/1529-0131(199904)42:43.0.CO;2-F; Мотовилов АА, Травина ИВ, Проказова НВ. Антитела к нейтральным гликосфинголипидам и ганглиозидам у больных системной красной волчанкой с поражением центральной нервной системы. Клиническая ревматология. 1995;(1):36-8 [Motovilov AA, Travina IV, Prokazova NV. Antibodies to neutral glycosphingolipids and gangliosides in patients with systemic lupus erythematosus with central nervous system damage. Klinicheskaya Revmatologiya. 1995;(1):36-8 (In Russ.)].; Насонова ВА, Сперанский АИ. Клинико-иммунологические субтипы системной красной волчанки. В кн.: Современные проблемы ревматологии. 1-й Съезд ревматологов России. Тезисы докладов. Оренбург; 1993. С. 121-2 [Nasonova VA, Speranskii AI. Clinical and immunological subtypes of systemic lupus erythematosus. In: Sovremennye problemy revmatologii. 1-i S"ezd revmatologov Rossii. Tezisy dokladov [Current problems of rheumatology. 1st Congress of Rheumatologists of Russia. Abstracts]. Orenburg; 1993. P. 121-2 (In Russ.)].; Пизова НВ, Шилкина НП, Спирин НН. Иммунные повреждения нервной системы при некоторых формах ревматических заболеваний. Журнал неврологии и психиатрии. 2005;(2):73-8 [Pizova NV, Shilkina NP, Spirin NN. Immune damage to the nervous system in some forms of rheumatic diseases. Zhurnal Nevrologii i Psikhiatrii. 2005;(2):73-8 (In Russ.)].; Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-47. doi:10.1038/nrrheum.2014.15. PMid:24514913; Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41-72. doi:10.1016/j.jaut.2016.06.013. PMID:27427403; Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484. doi:10.3389/fimmu.2013.00484; Fanouriakis A, Pamfil C, Rednic S, et al. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clin Exp Rheumatol. 2016;34(5):910-7. Epub 2016 Jul 26. PMID: 27463840.; Ho RC, Thiaghu C, Ong H, et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016;15:124-38. doi:10.1016/j.autrev.2015.10.003; Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015;13:43. doi:10.1186/s12916-015-0269-8. PMID:25858312; Алекберова ЗС, Решетняк ТМ, Рaденска-Лоповок СГ. Васкулопатия у больных системной красной волчанкой с антифосфолипидным синдромом. Терапевтический архив. 1995;(5):41-4 [Alekberova ZS, Reshetnyak TM, RadenskaLopovok SG. Vasculopathy in patients with systemic lupus erythematosus with antiphospholipid syndrome. Terapevticheskii Arkhiv. 1995;(5):41-4 (In Russ.)].; Hirohata S, Sakuma Y, Matsueda Y, et al. Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol. 2018;24. PMID: 29846157.; Cohen D, Rijnink EC, Nabuurs RJ, et al. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology (Oxford). 2017;56(1):77-86. doi:10.1093/rheumatology/kew341. Epub 2016 Oct 25.; Иванова ММ, Близнюк ОИ, Щекутьев ГА, Пушкова ОВ. Диагностика поражения центральной нервной системы у больных системной красной волчанкой. Клиническая ревматология. 1991;(4):6-8 [Ivanova MM, Bliznyuk OI, Shchekut'ev GA, Pushkova OV. Diagnosis of central nervous system lesions in patients with systemic lupus erythematosus. Klinicheskaya Revmatologiya. 1991;(4):6-8 (In Russ.)].; Zirkzee EJ, Steup-Beekman GM, van der Mast RC, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012;39(11):2118-26. doi:10.3899/jrheum.120545; Vivaldo JF, de Amorim JC, Julio PR, et al. Definition of NPSLE: Does the ACR Nomenclature Still Hold? Front Med (Lausanne). 2018 May 31;5:138. doi:10.3389/fmed.2018.00138; Иванова ММ, Близнюк ОИ, Тодау ФИ, Туманова АА. Поражение центральной нервной системы при системной красной волчанке. Клиническая медицина. 1989;(2):93-7 [Ivanova MM, Bliznyuk OI, Todau FI, Tumanova AA. Central nervous system damage in systemic lupus erythematosus. Klinicheskaya Meditsina. 1989;(2):93-7 (In Russ.)].; Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi:10.1002/art.22305; Иванова ММ. ЦНС-люпус: проблемы и достижения (результаты 10-летнего – клинико-инструментального исследования). Терапевтический архив. 2001;(6):25-9 [Ivanova MM. CNS-lupus: problems and achievements (results of a 10-year clinical and instrumental study). Terapevticheskii Arkhiv. 2001;(6):25-9 (In Russ.)].; Харченко СА, Грехов РА, Сулейманова ГП и др. Психологические особенности больных системной красной волчанкой. Современные проблемы науки и образования. 2015;(5) [Kharchenko SA, Grekhov RA, Suleimanova GP, et al. Psychological features of patients with systemic lupus erythematosus. Sovremennye Problemy Nauki i Obrazovaniya. 2015;(5) (In Russ.)].; Hussein MA, Elsabagh YA, Hosny A, Elgendy H. Silent cerebral MRI findings in lupus nephritis patients: is it clinically significamt? J Adv Res. 2017 Nov;20(9):63-7. doi:10.1016/j.jare.2017.10.011; Койлубаева ГМ, Асеева ЕА, Соловьев СК и др. Клинические проявления, варианты течения и исходы системной красной волчанки у жителей Кыргызстана. Научно-практическая ревматология. 2016;54(4):432-41 [Koilubaeva GM, Aseeva EA, Solovyev SK, et al. Clinical mani festations, courses, and outcomes of systemic lupus erythematosus in the dwellers of Kyrgyzstan. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):432-41 (In Russ.)]. doi:10.14412/1995-4484-2016-432-441].; Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928; Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.; Unterman A, Nolte JE, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41(1):1-11. doi:10.1016/j.semarthrit.2010.08.001; Benseler S, Silverman E. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus. 2007;16:564-71. doi:10.1177/0961203307078971; Popescu A, Kao AH. Neuropsychiatric Systemic Lupus Erythematosus. Curr Neuropharmacol. 2011;9(3):449-57. doi:10.2174/157015911796557984; Brey RL. Neuropsychiatric lupus: clinical and imaging aspects. Bull NYU Hosp Jt Dis. 2007;65(3):194-9.; Zirkzee EJ, Huizinga TW, Bollen EL, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23(1):31-8. doi:10.1177/0961203313512540; Dö ndü Üskü daz Cansu, Hava Üskü dar Teke, Gengiz Korkmaz. Survival analysis of Turkish patients with systemic lupus erythematosus: older age of diagnosis affects mortality. Arch Rheumatol. 2017;32(2):141-8. doi:10.5606/ArchRheumatol.2017.6173; Morad CS, Mansour HE, Ibrahim SE, et al. Subclinical neuropsychiatric dysfunctions in female patients with systemic lupus erythematosus. Egyptian Rheumatol Rehabil. 2018;45:49-56. doi:10.4103/err.err_46_17; Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001;45(5):419-23. doi:10.1002/1529-0131(200110)45:53.0.CO;2-X; Hanly JG. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus. 2004;13(11):861-4. doi:10.1191/0961203304lu2024oa; Birnbaum J, Petri M, Thompson R, et al. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60(11):3378-87. doi:10.1002/art.24937; Barber CE, Leclerc R, Gladman DD, et al. Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus. Semin Arthritis Rheum. 2011;41(3):353-63. doi:10.1016/j.semarthrit.2011.07.001; Ahn GY, Kim D, Won S, et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 2018 Jul;27(8):1338-47. doi:10.1177/0961203318772021; Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology. 2008;47:1498-502. doi:10.1093/rheumatology/ken260; Rowshani AT, Remans P, Rozemuller A, Tak PP. Cerebral vasculitis as a primary manifestation of systemic lupus erythematosus. Ann Rheum Dis. 2005;64:784-6. doi:10.1136/ard.2004.026542; Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: Prospective evaluation in a large cohort of Italian patients. Rheumatology. 2002;41:1357-66. doi:10.1093/rheumatology/41.12.1357; Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol. 2002;16(2):229-44. doi:10.1053/berh.2001.0223; Purandare KN, Wagle AC, Parker SR. Psychiatric morbidity in patients with systemic lupus erythematosus. Q J Med. 1999;92:283-6. doi:10.1093/qjmed/92.5.283; Kakati S, Barman B, Ahmed SU, Hussain M. Neurological Manifestations in Systemic Lupus Erythematosus: A Single Centre Study from North East India. J Clin Diagn Res Intern Med Sect. 2017;11(01):0C05-OCO9. doi:10.7860/JCDR/2017/23773.9280; Khajezadeh MA, Zamani G, Moazzami B, et al. Neuropsychiatric Involvement in Juvenile-Onset Systemic Lupus Erythematosus. Neurol Res Int. 2018 May 29:2548142. doi:10.1155/2018/2548142; Szmyrka M, Pokryszko-Dragan A, Slotwinski K, et al. Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus. Adv Clin Exp Med. 2018 Jul 2. doi:10.17219/acem/76711; Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus. Neurology. 2002;58:1214-20. doi:10.1212/WNL.58.8.1214PMid:11971089; Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage systemic lupus erythematosus: data from the Maryland lupus cohort. J Rheumatol. 2004;43:1555-60. doi:10.1093/rheumatology/keh384; Mok CC, Mak A, Chu WP, et al. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore). 2005;84:218-24. doi:10.1097/01.md.0000170022.44998.d1; Whitelaw DA, Spangenberg JJ, Rickman R, et al. Association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus. 1999;8:444-8. doi:10.1177/096120339900800606; Everett CM, Graves TD, Lad S, et al. Aggressive CNS lupus vasculitis in the absence of systemic disease activity. Rheumatology (Oxford). 2008;47:107-9. doi:10.1093/rheumatology/kem264; Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47:337-69. doi:10.1097/00005792-196807000-00002; Kleinig TJ, Koszyca B. Fulminant leucocytoclastic brainstem vasculitis in a patient with otherwise indolent systemic lupus erythematosus. Lupus. 2009;18:486-90. doi:10.1177/0961203308101548; Rizos T, Siegelin M, Hä hnel S, et al. Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2009;18:361-3. doi:10.1177/0961203308097448; Lukjanowcz M, Brzosko M. Myelitis in the course of systemic lupus erythematosus. Polskie Arch Med Wew. 2009;119(1-2):67-72.; Krishnan C, Kaplin AI, Deshpande DM, et al. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004;9:1483-99. doi:10.2741/1351; Toledano P, Orueta R, Rodriguez-Pinto I, et al. Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun Rev. 2017 Jul;16(7):750-5. doi:10.1016/j.autrev.2017.05.011; Saigal R, Bhargav R, Goyal L, et al. Peripheral Neuropathy in Systemic Lupus Erythematosus: Clinical and Electrophysiological Properties and their Association with Disease Activity Parameters. J Assoc Physicians India. 2015 Dec;63(12):15-9.; Huynh C, Ho SL, Fong KY, et al. Peripheral neuropathy in systemic lupus erythematosus. J Clin Neurophysiol. 1999;16(2):164-8. doi:10.1097/00004691-199903000-00010; Лайсэк РП, Левинсон АИ. Невропатии при заболеваниях соединительной ткани. Заболевания периферической нервной системы. Москва: Медицина; 1987. 280 с. [Laisek RP, Levinson AI. Nevropatii pri zabolevaniyakh soedinitel'noi tkani. Zabolevaniya perifericheskoi nervnoi sistemy [Neuropathy in connective tissue diseases. Peripheral nervous system diseases]. Moscow: Meditsina; 1987. 280 p. (In Russ.)].; Mondelli M, Romano C, Porta P, Rossi A. Electrophysiological evidence of «nerve entrapment syndromes» and subclinical peripheral neuropathy in progressive systemic sclerosis. J Neurol.

Availability: https://rsp.mediar-press.net/rsp/article/view/2669
https://doi.org/10.14412/1995-4484-2019-17-27

View record from BASE

18

Academic Journal

Влияние компьютеризации на физиологию нервной системы

Authors: Горбачева Инна Александровна, Inna A. Gorbacheva, Тютюнникова Евгения Борисовна, Evgeniia B. Tiutiunnikova

Source: Student science in the XXI century; № 1(12); 15-17 ; Студенческая наука XXI века; № 1(12); 15-17 ; ISSN: 2413-3825 ; 2413-3825

Subject Terms: революция, зависимость, научно-технический прогресс, головной мозг, компьютеризация, центральная нервная система, игромания, периферическая нервная система, вегетативная нервная система, соматическая нервная система, нервы, НТР

File Description: text/html

Relation: info:eu-repo/semantics/altIdentifier/pissn/2413-3825; https://interactive-plus.ru/e-articles/334/Action334-116985.pdf; 1. Гайвороннский И.В. Функциональная анатомия ЦНС: Учеб. Пособие для мед. вузов / И.В. Гайворонский, А.И. Гайворонский. – СПб.: Спец. Лит., 2007.; 2. Джуан С. Странности нашего тела. Занимательная анатомия / С. Джуан: Перевод с английского А.А. Давыдовой. – М.: Рипол классик, 2007.; 3. Конюховского П.В. Системы искусственного интеллекта и нейронные сети. Экономическая информатика / Под ред. П.В. Конюховского. – СПб.: Питер, 2010.; 4. Марютина Т.М. Введение в психофизиологию / Т.М. Марютина, О.Ю. Ермолаев. – М.: Флинта, 2001; 5. Сапин М.Р. Атлас нормальной анатомии человека / М.Р. Сапин – М.: Мед пресс информ, 2006–2007.

Availability: https://interactive-plus.ru/files/Books/Cover-334.jpg?req=116985
https://interactive-plus.ru/article/116985/discussion_platform

View record from BASE

19

Academic Journal

Методы получения информации в электромиографии

Authors: Ахметова Азалия Айдаровна, Azaliia A. Akhmetova, Демин Алексей Юрьевич, Aleksei I. Demin

Source: Новое слово в науке: перспективы развития; № 1(7); 21-23 ; ISSN: 2411-8133 ; 2411-8133

Subject Terms: ЭНМГ, периферическая нервная система, заданная электрическая мощность

File Description: text/html

Relation: info:eu-repo/semantics/altIdentifier/pissn/2411-8133; https://interactive-plus.ru/e-articles/201/Action201-16097.pdf; 1. Интегральная медицина XXI века Заболевания периферической нервной системы [Электронный ресурс]. – Режим доступа: http://www.it-med.ru/library/z/zabolevanie.htm; 2. Общая неврология / А.С. Никифоров, Е.И. Гусев. – 2007. – 720 с; 3. Неврология. Национальное руководство / Е.И. Гусев, В.И. Коновалов. – 2010. – 216 с.; 4. Демин А.Ю. Измерительные генераторы малой заданной электрической мощности // Вестник УГАТУ – 2005. – Т. 6. – №1 (12). – С. 88–94.; 5. Гусев В.Г. Принципы построения цифровых измерительных генераторов малой заданной электрической мощности с делителем на основе цифроаналогового преобразователя / В.Г. Гусев, И.А. Косулин // Вестник УГАТУ. – 2009. – Т. 12. – №2 (31). – С. 166–170.; 6. Гусев В.Г. Получение информации о параметрах и характеристиках организма и физические методы воздействия на него. –М.: Машиностроение, 2004 – 597 с.

Availability: https://interactive-plus.ru/files/Books/Cover-248.png?req=16097
https://interactive-plus.ru/article/16097/discussion_platform

View record from BASE

20

Academic Journal